Trisenox arsenic trioxide: Preliminary Phase II data

Preliminary data from an open-label, European Phase II trial in 115 high-risk (HR) and lower-risk (LR) MDS

Read the full 171 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE